IP Library Granted Patent US 12,491,189
Granted Patent B2
US 12,491,189 · App. 18/638,340 · Granted Dec 9, 2025

OTIC formulations, methods and devices

Inventors: Douglas I. Hepler (Overland Park, KS); Gail L. Dempsey (Overland Park, KS); Dorothea A. Erxleben (Overland Park, KS); Neil E. Paulsen (Overland Park, KS)
Assignee: Dechra Veterinary Products, LLC
A61K31/573A61D7/00A61K9/0046A61K31/137A61K31/4174A61K31/5395A61K31/56A61K31/58A61K47/44A61M31/00A61P27/16A61P31/00A61M2210/0662
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,491,189
App. No.
18/638,340
Granted
Dec 9, 2025
Kind
B2
Abstract

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and/or clotrimazole and dexamethasone.

Claims (44)

1 . A method for treating an infection in an ear canal of a mammal, comprising applying a single dose of an otic formulation into the ear canal of a mammal with an ear infection, the otic formulation comprising:

a) therapeutic agents consisting of:

i) about 1.5% to 1.9% w/w of marbofloxacin;

ii) about 1.6% to 3.3% w/w of terbinafine or salts thereof; and

iii) about 0.1% to 0.3% w/w of dexamethasone; wherein the formulation further comprises,

b) about 17% to 26% w/w of wax; and

c) about 70% to 80% w/w of mineral oil.

2 . The method of claim 1 , wherein the formulation is in a flowable fluid form that can be delivered to an ear canal of a mammal.

3 . The method of claim 2 , wherein upon introduction into the ear canal the formulation remains in the ear canal for at least 3 days releasing the therapeutic agents.

4 . The method of claim 1 , wherein the formulation has a viscosity of about 10-80,000 cPs at 37° C.

5 . The method of claim 1 , wherein the otic formulation comprises:

a) therapeutic agents consisting of:

i) about 1.5% to 1.9% w/w of marbofloxacin;

ii) about 1.6% to 2.0% w/w of terbinafine or salts thereof; and

iii) about 0.1% to 0.25% w/w of dexamethasone; wherein the formulation further comprises;

b) about 78% to 80% w/w mineral oil; and

c) about 17% to 18% w/w paraffin.

6 . The method of claim 5 , wherein after applying to an ear canal of a mammal having an ear infection, the formulation remains in the ear canal and has a viscosity of about 10-80,000 cPs at 37° C.

7 . The method of claim 1 , wherein the formulation comprises

a) therapeutic agents consisting of:

(i) about 1.50% to 1.9% w/w of marbofloxacin,

(ii) about 2.7% to 3.3% w/w of terbinafine,

(iii) about 0.1% to 0.3% w/w of dexamethasone, wherein the formulation further comprises:

b) about 22% to 26% w/w of wax, and

c) about 70% to 74% w/w of mineral oil.

8 . The method of claim 1 , wherein the formulation is for single treatment and has a clinical cure rate of at least 90% within a duration of less than 27 days.

9 . The method of claim 1 , the otic formulation comprising therapeutic agents consisting of about 1.5% to 1.9% w/w of marbofloxacin, about 1.6% to 3.3% w/w of terbinafine or salts thereof and about 0.1% to 0.3% w/w dexamethasone, wherein the formulation further comprises an aurally acceptable carrier wherein the carrier comprises about 17% to 26% w/w of wax; and about 70% to 80% w/w of mineral oil,

the carrier having about 10-80,000 cPs at 37° C., wherein the carrier retains the marbofloxacin, the terbinafine, and the dexamethasone in an ear for 7-14 days and then egresses or is absorbed, and wherein the formulation is for single treatment and has a clinical cure rate of at least 90% within a duration of less than 27 days.

10 . The method of claim 1 , wherein the ear infection is clinically resolved within a duration of about 27 days.

11 . The method of claim 10 , wherein the mammal is a human, canine or feline.

12 . The method of claim 1 , the otic formulation comprising:

a) therapeutic agents consisting of:

i) about 1.5% to 1.9% w/w of marbofloxacin;

ii) about 2.7% to 3.3% w/w of terbinafine or salts thereof; and

iii) about 0.1% to 0.3% w/w of dexamethasone; wherein the formulation further comprises,

b) about 70% to 74% w/w mineral oil; and

c) about 22% to 26% w/w paraffin.

13 . The method of claim 1 , the otic formulation comprising:

a) therapeutic agents consisting of:

i) about 1.5% to 1.9% w/w of marbofloxacin;

ii) about 2.7% to 3.3% w/w of terbinafine or salts thereof; and

iii) about 0.1% to 0.3% w/w of dexamethasone; wherein the formulation further comprises,

b) about 71% to 72% w/w mineral oil; and

c) about 23% to 24% w/w paraffin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2024
From: PIEDMONT ANIMAL HEALTH LLC
To: DECHRA VETERINARY PRODUCTS, LLC
Reel/Frame 067843/0131 →
CHANGE OF NAME Recorded Jun 26, 2024
From: PIEDMONT ANIMAL HEALTH INC.
To: PIEDMONT ANIMAL HEALTH LLC
Reel/Frame 067846/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2024
From: HEPLER, DOUGLAS I.; DEMPSEY, GAIL L.; PAULSEN, NEIL E.; ERXLEBEN, DOROTHEA A.
To: PIEDMONT ANIMAL HEALTH INC.
Reel/Frame 067710/0276 →
Continuity (3)
Continuation 17066343 · Oct 8, 2020
Provisional Application 62914301 · Oct 11, 2019
Related Publication 20240285651A1 · Aug 29, 2024
References Cited (16)
US 11986483B2 · Hepler · 2024 [cited by examiner]
US 20050239722A1 · Albert · 2005 [cited by applicant]
US 20070078116A1 · Lane · 2007 [cited by applicant]
US 20100036000A1 · Lichter et al. · 2010 [cited by applicant]
US 20130178801A1 · Branch · 2013 [cited by applicant]
US 20150297588A1 · Branch · 2015 [cited by examiner]
US 20160058775A1 · Prasad et al. · 2016 [cited by applicant]
JP 2008504271A · 2008 [cited by applicant]
Bensignore et al., “Comparison of an Antifungal Agent with a Mixture of Antifungal, Antibiotic and Corticosteroid Aents for the Treatment of Malassezia Species Otitis in Dogs,” [cited by applicant]
EP Extended Search Report in European Application No. 20874331.0 dated Sep. 22, 2023, 6 pages. [cited by applicant]
Law Insider Dictionary, Therapeutic Agent Definition. Retrieved from the Internet on Jan. 19, 2024, https://www.lawinsider.com/dictionary/therapeutic-agent, (2024). [cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2020/054770 dated Jan. 13, 2021, 11 pages. [cited by applicant]
Veterinary Dermatology, “Plenary Session Abstracts: Thursday Morning, Jul. 26 Theme: Allergy,” [cited by applicant]
JP Office Action in Japanese Application No. 2022-521440, dated Aug. 22, 2024, 8 pages (with English translation). [cited by applicant]
Rougier et al., “A Comparative Study of Two Antimicrobial/Anti-Inflammatory Formulations in the Treatment of Canine Otitis Externa”, Veterinary Dermatology, 2005, vol. 16, pp. 299-307. [cited by applicant]
Veterinary Medicines Directorate, “Publicly Available Assessment Report for a Veterinary Medicinal Product,” Marbodex Aural Ear Drops, Suspension for Dogs, Sep. 2015, Retrieved from Internet URL: https://www.vmd.defra.g… [cited by applicant]